• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.

作者信息

Catoggio L J, Skinner R P, Maddison P J

出版信息

Rheumatol Int. 1983;3(1):19-21. doi: 10.1007/BF00541227.

DOI:10.1007/BF00541227
PMID:6412349
Abstract

To determine the clinical significance of anti-centromere (ACA) and anti Scl-70 antibodies in an English population with connective tissue diseases, we examined the sera of 150 patients, including 40 with systemic sclerosis (SS), who were prospectively studied on the same clinical protocol in our connective tissue disease clinic. ACA was present in 44% of the CREST patients as opposed to only 12% of those with SS and diffuse skin involvement. Only two patients without SS had ACA. Anti Scl-70 was detected in 20% of the patients with SS and only two of those with other connective tissue diseases. We confirmed the specificity of these antibodies for SS. Either anti Scl-70 or ACA was present in half the patients with SS and their presence may represent a useful aid to diagnosis of this disease in patients presenting with Raynaud's phenomenon or an undifferentiated connective tissue disease. While less than half the CREST patients had ACA, this antibody appears to identify those patients within the CREST variant with skin involvement confined to sclerodactyly as opposed to those with acrosclerosis. These patients, however, did not differ in the degree of visceral involvement.

摘要

相似文献

1
Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.
Rheumatol Int. 1983;3(1):19-21. doi: 10.1007/BF00541227.
2
[Significance of anti-centromere antibodies. Clinical value].[抗着丝点抗体的意义。临床价值]
Rev Rhum Mal Osteoartic. 1983 Apr;50(4):261-6.
3
Clinical and serological heterogeneity in patients with anticentromere antibodies.抗着丝点抗体患者的临床和血清学异质性
J Rheumatol. 2005 Aug;32(8):1488-94.
4
[Anti-Scl-70 antibodies in systemic scleroderma].[系统性硬化症中的抗Scl-70抗体]
Ann Dermatol Venereol. 1990;117(2):103-7.
5
Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.抗着丝点抗体:系统性硬化症一个亚群的免疫学标志物。
Br J Dermatol. 1985 Oct;113(4):381-9. doi: 10.1111/j.1365-2133.1985.tb02351.x.
6
[The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].[抗可提取核抗原(ENA)抗体和抗着丝点抗体(ACA)在硬皮病样皮肤改变和雷诺现象患者中的临床意义]
Ryumachi. 1984 Aug;24(4):241-9.
7
The CREST syndrome: a distinct serologic entity with anticentromere antibodies.CREST综合征:一种具有抗着丝点抗体的独特血清学实体。
Am J Med. 1980 Oct;69(4):520-6. doi: 10.1016/0002-9343(80)90462-3.
8
Scl 70 antibody--a specific marker of systemic sclerosis.Scl 70抗体——系统性硬化症的特异性标志物。
Br J Dermatol. 1986 Oct;115(4):393-401. doi: 10.1111/j.1365-2133.1986.tb06233.x.
9
Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.通过免疫印迹法在进行性系统性硬化症中检测抗Scl-70抗体:特异性及临床相关性
Ann Rheum Dis. 1989 Dec;48(12):992-7. doi: 10.1136/ard.48.12.992.
10
[Anticentromere antibodies. Diagnostic and prognostic value].[抗着丝点抗体。诊断和预后价值]
Nouv Presse Med. 1982 Oct 9;11(39):2891-4.

引用本文的文献

1
Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?根据皮肤受累范围,局限性系统性硬化症是否存在临床差异?
Int J Rheumatol. 2014;2014:716358. doi: 10.1155/2014/716358. Epub 2014 Nov 11.
2
Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.系统性硬化症患者中抗拓扑异构酶I抗体与抗着丝粒抗体的共存。
Ann Rheum Dis. 2002 Feb;61(2):121-7. doi: 10.1136/ard.61.2.121.
3
Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

本文引用的文献

1
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.系统性硬化症(硬皮病)分类的初步标准。美国风湿病协会诊断与治疗标准委员会硬皮病标准小组委员会。
Arthritis Rheum. 1980 May;23(5):581-90. doi: 10.1002/art.1780230510.
2
Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.进行性系统性硬化症中抗核抗体与抗核仁抗体的关联。
Clin Exp Immunol. 1982 Apr;48(1):43-51.
3
The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
系统性硬化症中抗RNA聚合酶抗体的临床和血清学关联
Clin Exp Immunol. 1999 Aug;117(2):395-402. doi: 10.1046/j.1365-2249.1999.00964.x.
4
Anticentromere antibody--clinical associations. A study of 44 patients.抗着丝点抗体——临床关联。44例患者的研究。
Rheumatol Int. 1995;14(6):253-5. doi: 10.1007/BF00262092.
5
Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.硬皮病的发病机制:免疫假说与血管假说的相互关系
Surv Immunol Res. 1985;4(1):69-80. doi: 10.1007/BF02918588.
6
Differential isotype recognition of two centromere associated polypeptides by immunoblotting in connective tissue disease.在结缔组织病中通过免疫印迹法对两种着丝粒相关多肽进行差异性同种型识别。
Clin Exp Immunol. 1988 Jun;72(3):457-64.
7
Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.通过免疫印迹法在进行性系统性硬化症中检测抗Scl-70抗体:特异性及临床相关性
Ann Rheum Dis. 1989 Dec;48(12):992-7. doi: 10.1136/ard.48.12.992.
8
Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.硬皮病患者的Scl 70自身抗体可识别一种被鉴定为DNA拓扑异构酶I的95 kDa蛋白质。
Chromosoma. 1986;94(2):132-8. doi: 10.1007/BF00286991.
9
Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma).HLA-DQB1第一结构域第26位极性氨基酸与系统性硬化症(硬皮病)中抗着丝点自身抗体反应的关联。
J Clin Invest. 1992 Apr;89(4):1208-13. doi: 10.1172/JCI115704.
10
Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).HLA-DQB1第一结构域氨基酸序列与硬皮病(进行性系统性硬化症)中抗拓扑异构酶I自身抗体反应的关联
J Clin Invest. 1992 Sep;90(3):973-80. doi: 10.1172/JCI115974.
CREST综合征:一种具有抗着丝点抗体的独特血清学实体。
Am J Med. 1980 Oct;69(4):520-6. doi: 10.1016/0002-9343(80)90462-3.
4
Autoantibody to centromere (kinetochore) in scleroderma sera.硬皮病血清中的着丝粒(动粒)自身抗体。
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1627-31. doi: 10.1073/pnas.77.3.1627.
5
Serological markers in progressive systemic sclerosis: clinical correlations.进行性系统性硬化症的血清学标志物:临床相关性
Ann Rheum Dis. 1983 Feb;42(1):23-7. doi: 10.1136/ard.42.1.23.
6
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.进行性系统性硬化症中抗核抗体的多样性。抗着丝点抗体及其与CREST综合征的关系。
Arthritis Rheum. 1980 Jun;23(6):617-25. doi: 10.1002/art.1780230602.
7
Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera.一种与系统性红斑狼疮血清反应的可溶性核糖核蛋白抗原的特性分析。
J Immunol. 1971 Nov;107(5):1281-90.
8
Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.一种与系统性红斑狼疮患者血清反应的可溶性细胞质抗原的特性分析。
J Immunol. 1969 Jan;102(1):117-22.
9
Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.鉴定一种核蛋白(Scl-70)为硬皮病中人类抗核抗体的独特靶标。
J Biol Chem. 1979 Oct 25;254(20):10514-22.